secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-068614
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026
--------------------------------------------------------------------------------

- 100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.
- Favorable safety profile: no Grade ≥3 CRS or ICANS across dose levels in REDEEM-1.
- Prior 24-patient IIT showed 89.5% CR rate and median progression-free survival of 23.1 months.
- Tempest plans to submit U.S. IND and initiate registrational study of TPST-2003 in 2026, subject to clearance.
- Company exploring TPST-2003 in LBCL; expects initial data from TPST-3003 and TPST-4003 programs later in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/0001193125-26-068614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/d22967d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-068614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer